The pharmacology and clinical evidence for the use of dual versus single antiplatelet therapy
The landscape of antiplatelet treatment regimens has significantly evolved over time, with the current trend being toward a tailored approach based on risk profile, aiming to reduce the risk of bleeding while maintaining ischemic protection. The accurate evaluation of each patient's ischemic and bleeding risk profile is of utmost importance. Dedicated tools have been developed to optimize patient risk profiling and help guide the selection of the antiplatelet regimen. Based on risk estimation, several strategies can be used to reduce the overall risk, including the selection and duration of the antiplatelet regimen.
Authors
- Francesco Franchi
- Ali Zgheib (ORCID: https://orcid.org/0000-0002-6888-5429)
- G OCCHIPINTI
- Fabiana Rollini (ORCID: https://orcid.org/0000-0002-2295-7140)
- Claudio Laudani (ORCID: https://orcid.org/0000-0001-5467-7402)
- Marco Spagnolo (ORCID: https://orcid.org/0000-0002-5434-607X)
- Maryam Farahmandsadr (ORCID: https://orcid.org/0000-0003-1890-5839)
- Mohmmad M. Alawajneh (ORCID: https://orcid.org/0000-0002-9563-8060)
- Davide Capodanno (ORCID: https://orcid.org/0000-0002-5156-7723)
- Dominick J Angiolillo
- Luis Ortega-Paz
- Georges El Khoury
Institutions
- University of Florida (US)
- University of Catania (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Expert Review of Clinical Pharmacology
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/17512433.2026.2612770
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00